Vaporox Inc

Vaporox is at the forefront of innovation in chronic wound care, offering advanced solutions with our patented Vaporous Hyperoxia Therapy (VHT™). Our FDA-cleared technology targets and treats chronic wounds, including diabetic foot ulcers and pressure ulcers, with a proven success rate of healing 84% of cases when used alongside standard wound care. Designed for patient comfort and efficiency, VHT uses ultrasonic waves to deliver concentrated oxygen and water vapor deep into the wound tissue, accelerating healing from the inside out. This breakthrough approach not only enhances patient outcomes but also reduces the overall cost of care for healthcare providers. Our device has consistently shown granulation of wound beds by 50-70% in volume within 4-6 weeks. We partner with skilled nursing facilities, clinics, and wound care centers to integrate VHT seamlessly, empowering them to elevate their standards of care without the need for upfront investment. Vaporox remains dedicated to enhancing our technology to meet the evolving needs of chronic wound care.